Biotech Values

[rfj1862]

The FDA proposed those endpoints and confirmed that they were likely to predict clinical benefit to support accelerated approval.

There are very few instances where the FDA has specified appropriate endpoints, the endpoints were met in clinical trials without major safety concerns, and the FDA failed to approve.

While your idea isn't completely outside the bounds of reality, it's a bit of a reach.